Belzutifan with Lenvatinib in Patients with Advanced Renal Cell Carcinoma

Belzutifan in combination with lenvatinib are in clinical development for the treatment of adults with advanced clear cell renal cell carcinoma (RCC) after previous treatment. Clear cell RCC is the most common type of kidney cancer and is named after how the tumour looks under the microscope. Because early-stage RCC often goes undetected, approximately 16% of patients present with advanced RCC, which is defined as stage IV disease that may or may not include metastasis. Most patients with RCC are usually asymptomatic in the early stage, but symptoms that appear as the cancer progresses, includes blood in the urine, anaemia (not enough healthy red blood cells), flank pain, weight loss and fatigue. Treatment options for RCC in the late-line setting after previous treatments are limited.